医院与出院后质量改进干预对射血分数降低心衰患者临床结局与照护质量的影响:CONNECT-HF随机临床试验
CONNECT-HF集群随机试验纳入161家美国医院的5647例HFrEF患者,比较医院与出院后质量改进干预(82家医院)与常规照护(79家医院)的效果。干预组心衰再住院或全因死亡发生率为38.6%,常规组为39.2%(校正HR 0.92,95%CI 0.81-1.05)。照护质量复合评分变化两组差异无统计学意义(差值3.3%,95%CI -0.8%至7.3%)。
要点
- 质量改进干预未显著降低HFrEF患者心衰再住院或全因死亡风险。
- 干预未显著改善基于机会的照护质量复合评分。
- 该干预策略未能达到改善HFrEF临床结局与照护质量的目标。
核心结论
- 在HFrEF患者中,医院与出院后质量改进干预相比常规照护,未显著改善首次心衰再住院或死亡时间,也未显著改善照护质量复合评分变化。
研究设计与样本
- 集群随机临床试验,纳入161家美国医院,5647例急性心衰出院后HFrEF患者(干预组2675例,常规组2972例),2017年至2020年进行,最终随访日期2020年8月31日。
主要发现
- 心衰再住院或全因死亡在干预组发生38.6%,常规组39.2%(校正HR 0.92,95%CI 0.81-1.05)。
- 照护质量评分基线干预组42.1%、常规组45.5%,随访变化分别为2.3%和-1.0%(差值3.3%,95%CI -0.8%至7.3%)。
- 末次随访时达到更高复合质量评分的几率两组无显著差异(校正OR 1.06,95%CI 0.93-1.21)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adoption of guideline-directed medical therapy for patients with heart failure is variable. Interventions to improve guideline-directed medical therapy have failed to consistently achieve target metrics, and limited data exist to inform efforts to improve heart failure quality of care. OBJECTIVE: To evaluate the effect of a hospital and postdischarge quality improvement intervention compared with usual care on heart failure outcomes and care. DESIGN, SETTING, AND PARTICIPANTS: This cluster randomized clinical trial was conducted at 161 US hospitals and included 5647 patients (2675 intervention vs 2972 usual care) followed up after a hospital discharge for acute heart failure with reduced ejection fraction (HFrEF). The trial was performed from 2017 to 2020, and the date of final follow-up was August 31, 2020. INTERVENTIONS: Hospitals (n = 82) randomized to a hospital and postdischarge quality improvement intervention received regular education of clinicians by a trained group of heart failure and quality improvement experts and audit and feedback on heart failure process measures (eg, use of guideline-directed medical therapy for HFrEF) and outcomes. Hospitals (n = 79) randomized to usual care received access to a generalized heart failure education website. MAIN OUTCOMES AND MEASURES: The coprimary outcomes were a composite of first heart failure rehospitalization or all-cause mortality and change in an opportunity-based composite score for heart failure quality (percentage of recommendations followed). RESULTS: Among 5647 patients (mean age, 63 years; 33% women; 38% Black; 87% chronic heart failure; 49% recent heart failure hospitalization), vital status was known for 5636 (99.8%). Heart failure rehospitalization or all-cause mortality occurred in 38.6% in the intervention group vs 39.2% in usual care (adjusted hazard ratio, 0.92 [95% CI, 0.81 to 1.05). The baseline quality-of-care score was 42.1% vs 45.5%, respectively, and the change from baseline to follow-up was 2.3% vs -1.0% (difference, 3.3% [95% CI, -0.8% to 7.3%]), with no significant difference between the 2 groups in the odds of achieving a higher composite quality score at last follow-up (adjusted odds ratio, 1.06 [95% CI, 0.93 to 1.21]). CONCLUSIONS AND RELEVANCE: Among patients with HFrEF in hospitals randomized to a hospital and postdischarge quality improvement intervention vs usual care, there was no significant difference in time to first heart failure rehospitalization or death, or in change in a composite heart failure quality-of-care score. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03035474.
引用
- DeVore AD, Granger BB, Fonarow GC, et al. Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. JAMA. 2021. PMID: 34313687. doi:10.1001/jama.2021.8844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。